謝謝，瑞冬兄幫忙科普! 這裏再解釋一下 ONCOCIDIA 抗癌化繁為簡的道理，幹脆用英文，希望這樣就不困擾非專業的朋友。
Cancer is not one, but many diseases with multiple diverse mutations, genotypes, phenotypes, pathways, downstream effectors, upstream mediators, signalings, factors, biomarkers, … …, each of which is supposed to be individually tackled by so called -omics-based personalized medicine in a fashionable way. Such an increasingly known complexity makes cancer cure almost a mission impossible. In another word, there is no single target available in all cancers, suggesting why anticancer war has been so difficult to win so far.
In contrast, with our dual targeting ONCOCIDIA approach, by using noninvasive vascular disrupting agents such as CA4P or using minimally invasive methods such as RFA, we can easily make tumor necrosis, which in turn becomes a single target common to all cancers. Then, we label a necrosis-avid compound such as hypericin with a therapeutic radionuclide such as idine-131, a beta emitter used for the treatment of thyroid cancer, and inject the agent intravenously to kill all the adjacent residual viable tumor cells within the penetration range of the crossfire targeted radiotherapy, hence cancer cure. The gamma ray of idine-131 can be used in nuclear imaging for tumor detection and therapeutic follow up.
Cancer is not one, but many diseases with multiple diverse mutations, genotypes, phenotypes, pathways, downstream effectors, upstream mediators, signalings, factors, biomarkers, … …, each of which is supposed to be individually tackled by so called -omics-based personalized medicine in a fashionable way. Such an increasingly known complexity makes cancer cure almost a mission impossible. In another word, there is no single target available in all cancers, suggesting why anticancer war has been so difficult to win so far.
In contrast, with our dual targeting ONCOCIDIA approach, by using noninvasive vascular disrupting agents such as CA4P or using minimally invasive methods such as RFA, we can easily make tumor necrosis, which in turn becomes a single target common to all cancers. Then, we label a necrosis-avid compound such as hypericin with a therapeutic radionuclide such as idine-131, a beta emitter used for the treatment of thyroid cancer, and inject the agent intravenously to kill all the adjacent residual viable tumor cells within the penetration range of the crossfire targeted radiotherapy, hence cancer cure. The gamma ray of idine-131 can be used in nuclear imaging for tumor detection and therapeutic follow up.
選擇“Disable on www.wenxuecity.com”
選擇“don't run on pages on this domain”
